NICE reviews its guidance against sequential use of anti-TNF drugs for arthritis

BMJ 2007; 334 doi: (Published 14 June 2007) Cite this as: BMJ 2007;334:1238
  1. Susan Mayor
  1. London

    The National Institute for Health and Clinical Excellence (NICE), the independent body that advises the NHS in England and Wales on use of treatments, has agreed to review its draft guidance against the sequential use of different tumour necrosis factor α (TNF-α) inhibitors in patients with rheumatoid arthritis, after an appeal from a group representing patients.

    In its appraisal published in November 2006 NICE recommended the TNF-α inhibitors adalimumab, etanercept, and infliximab as options in the treatment of adults who have active rheumatoid arthritis as determined by a disease activity score >5.1 confirmed on at least two occasions one month apart and who have undergone trials of two disease modifying antirheumatic …

    View Full Text

    Sign in

    Log in through your institution